ethyl 3-{6-[(tert-butoxycarbonyl)amino]pyridin-3-yl}-2-[(propanoylselanyl)methyl]propanoate | 304873-88-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 3-{6-[(tert-butoxycarbonyl)amino]pyridin-3-yl}-2-[(propanoylselanyl)methyl]propanoate
• 英文别名: 2-(6-tert-butoxycarbonylaminopyridin-3-ylmethyl)acrylic acid ethyl ester；Ethyl 2-({6-[(tert-butoxycarbonyl)amino]pyridin-3-yl}methyl)acrylate；ethyl 2-[[6-[(2-methylpropan-2-yl)oxycarbonylamino]pyridin-3-yl]methyl]prop-2-enoate
• CAS: 304873-88-9
• 化学式: C₁₆H₂₂N₂O₄
• 分子量: 306.362
• InChiKey: XXZDPEORSFAABI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  77.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 3-{6-[(tert-butoxycarbonyl)amino]pyridin-3-yl}-2-[(propanoylselanyl)methyl]propanoate 在 盐酸 、 四氧化锇 、 N-甲基吗啉氧化物 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 水 、 丙酮 为溶剂， 反应 94.0h， 生成 2-sulfanylmethyl-3-(6-aminopyridin-3-yl)-2-hydroxypropionic acid hydrochloride
  参考文献：
  名称：

  Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)

  摘要：

  A series of 3-mercapto-propionic acid derivatives that function as reversible inhibitors of carboxypeptidase U have been prepared. We present a successful design strategy using cyclic, low basicity guanidine mimetics resulting in potent, selective and bioavailable inhibitors of carboxypeptidase U (TAFla). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.12.039
• 作为产物：
  描述：

  2-(6-tert-butoxycarbonylaminopyridin-3-ylmethyl)malonic acid monoethyl ester 、 聚合甲醛 在 二乙胺 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 16.0h， 以83%的产率得到ethyl 3-{6-[(tert-butoxycarbonyl)amino]pyridin-3-yl}-2-[(propanoylselanyl)methyl]propanoate
  参考文献：
  名称：

  Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)

  摘要：

  A series of 3-mercapto-propionic acid derivatives that function as reversible inhibitors of carboxypeptidase U have been prepared. We present a successful design strategy using cyclic, low basicity guanidine mimetics resulting in potent, selective and bioavailable inhibitors of carboxypeptidase U (TAFla). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.12.039

文献信息

• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2000066557A1

  公开（公告）日：2000-11-09

  The present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

  本发明涉及式(I)的化合物，以及其药学上可接受的盐或溶剂，或这些盐的溶剂，这些化合物抑制羧肽酶U，因此可用于预防和治疗与羧肽酶U相关的疾病。在进一步方面，本发明涉及用于治疗的本发明化合物；制备这些新化合物的过程；包含本发明化合物中至少一种，或其药学上可接受的盐或溶剂的制药组合物，作为活性成分；以及在制造上述医疗用途的药物中使用活性化合物。
• Chemical compounds
  申请人：——

  公开号：US20040248852A1

  公开（公告）日：2004-12-09

  The present invention concerns compounds of formula (I), and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, 1 which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases where inhibition of carboxypeptidase U is beneficial. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

  本发明涉及式（I）的化合物，以及其药学上可接受的盐或溶剂化物，或这种盐的溶剂化物，1这些化合物抑制羧肽酶U，因此可用于预防和治疗抑制羧肽酶U有益的疾病。在进一步方面，本发明涉及本发明中化合物的治疗用途；制备这种新化合物的过程；包含本发明中至少一种化合物或其药学上可接受的盐或溶剂化物的制药组合物作为活性成分；以及将活性化合物用于制造上述医疗用途的药物。
• Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors
  申请人：Linschoten Marcel

  公开号：US20060079484A1

  公开（公告）日：2006-04-13

  The present invention relates to compounds of Formula I, and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

  本发明涉及I式化合物及其药学上可接受的盐或溶剂，或这些盐的溶剂，这些化合物抑制羧肽酶U，因此可用于预防和治疗与羧肽酶U相关的疾病。此外，本发明还涉及用于治疗的本发明化合物；制备这些新化合物的过程；包含本发明化合物中至少一种作为活性成分的药物组合物；以及在制造上述医疗用途的药物中使用活性化合物。
• Pyridine mercapto carboxylic acids as carboxypeptidase U inhibitors
  申请人：Astrazeneca AB

  公开号：US07071175B1

  公开（公告）日：2006-07-04

  The present invention relates to compounds of Formula I, and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds: to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.

  本发明涉及式I的化合物，以及其药学上可接受的盐或溶剂或这些盐的溶剂，这些化合物抑制羧肽酶U，因此可用于预防和治疗与羧肽酶U相关的疾病。在进一步方面，本发明涉及用于治疗的本发明化合物；制备这种新化合物的过程；包含本发明化合物中至少一种作为活性成分的药物组合物；以及在制造上述医疗用途的药物中使用活性化合物。
• Design and Characterization of a Selenium-Containing Inhibitor of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa), a Zinc-Containing Metalloprotease
  作者：Nobuko Yoshimoto、Tomoyuki Sasaki、Katsuyoshi Sugimoto、Hidemi Ishii、Keiko Yamamoto

  DOI：10.1021/jm300735t

  日期：2012.9.13

  Available therapies for thromboembolic disorders include thrombolytics, anticoagulants, and antiplatelets, but these are associated with complications such as bleeding. To develop an alternative drug which is clinically safe, we focused on activated thrombin-activatable fibrinolysis inhibitor (TAFIa) as the target molecule. TAFIa is a zinc-containing carboxypeptidase that significantly inhibits fibrinolysis. Here we designed and synthesized selenium-containing compounds 5-13 to discover novel TAFIa inhibitors having a superior zinc-coordinating group. Compounds 5-13 significantly inhibited TAFIa activity (IC50 2.2 x 10(-12) M - 2.6 x 10(-6) M). We found that selenol is a better functional group than thiol for coordinating to zinc at the active site of TAFIa. Furthermore, compound 12, which has an amino-chloro-pyridine ring, was found to be a potent and selective TAFIa inhibitor that lacks carboxypeptidase N inhibitory activity. Therefore, compound 12 is a promising candidate for the treatment of thromboembolic disorders. This is the first report of a selenium-containing inhibitor for TAFIa.